India, May 22 -- Shares of Instil Bio, Inc. (TIL) gained nearly 15% on Thursday morning after Instil and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced clinical trial updates of '2510 and NSCLC clinical development strategy.
TIL is currently trading at $18.65, up $2.43 or 14.98%, on the Nasdaq. The stock opened its trading at $18.50 after closing Wednesday at $16.22. The stock has traded between $9.62 and $92.00 in the past 52-week period.
"We are delighted with the significant clinical advancements by our collaborator, ImmuneOnco, with '2510 for NSCLC in China," said Bronson Crouch, CEO of Instil. "We are confident that '2510 has the potential to emerge as a leading PD-(L)1xVEGF bispecific antibody, and we look forward to the in...